Those at the top must walk the walk of uncompromising commitment to compliance
A high-performance anion exchange resin performs well compared with membranes. In addition, the resin offers greater flexibility and cost savings.
Industry may be its own obstacle to success in achieving the desired high-performance state.
Newer classes of biotherapies will require innovations in processing technology.
The authors describe an industrialized process for the manufacture of iPSC-derived human cardiomyocytes.
Industry may be its own obstacle to success in achieving the desired high-performance state.
A series of advancements has changed the way bioprocesses are developed and optimized.
Overcoming limitations of volumetric techniques and detecting transparent particles.
The authors re-examine environmental controls in the context of technical advances in manufacturing.
To achieve manufacturing excellence, biopharma companies must adopt four key operating principles.
Single-use TFF offers the greatest savings in clinical and contract manufacturing, where the scale is low and changeovers are frequent.
Switching to single-use bioreactors can have financial and performance benefits.
Newer classes of biotherapies will require innovations in processing technology.
How to strike a balance between site autonomy and global coordination.
The authors describe considerations and best practices for meeting drug substance uniformity.
Reliably detecting low amounts of high molecular weight impurities during process development and characterization of biopharmaceutical products.
Making chemically defined media work.
The authors provide insight into microRNA biology, and the simplicity of anti-miR oligonucleotide drug delivery.
Newer classes of biotherapies will require innovations in processing technology.
Achieving multiproduct development within shortened timelines.
Switching to single-use bioreactors can have financial and performance benefits.
Managing partnerships for the greater good.
Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant production.
Cellular therapy developers learn process development strategies from pharma industry experiences.
The authors take a look at the past and future impact of the Indian Pharmacopoeia Commission.
Fed-batch processes were scaled up from traditional bench-scale bioreactors to large-scale single-use systems.
The authors offer insight into cell therapy manufacturing, vector production, and the safety aspects of testing for characterization.
Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant production.
The authors take a look at the past and future impact of the Indian Pharmacopoeia Commission.